Patents by Inventor Martin A. Maier

Martin A. Maier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEGylated lipids and their use for drug delivery
    Patent number: 9999673
    Abstract: The invention provides poly(ethylene glycol)-lipid conjugates for use in drug delivery.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: June 19, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kallanthottathil G. Rajeev, Muthiah Manoharan, Muthusamy Jayaraman, Martin Maier, Jayaprakash K. Nair, David Butler
  • Treatment of the wastewater from isophorone production comprising neutralization, filtration and a downstream chemical oxidation process and subsequent reduction
    Patent number: 9994472
    Abstract: Treatment of the wastewater from isophorone production comprising neutralization, filtration and a downstream chemical oxidation process and subsequent reduction. The invention relates to treatment of the wastewater from isophorone (IP) production comprising neutralization, filtration and a downstream chemical oxidation process and subsequent reduction.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: June 12, 2018
    Assignee: Evonik Degussa GmbH
    Inventors: Yue Chang, Manfred Kreczinski, Martin Maier, Matthias Woyciechowski
  • Safety Module for an Automation System, Method for Operating a Safety Module in an Automation System and Automation System
    Publication number: 20180143604
    Abstract: A safety module for an automation system including a communication interface, which is configured for a signal-transmitting connection to a communication system including an output interface, which is configured for a signal-transmitting connection to consumers, which can be attached downstream, and including a processing device which is connected to both interfaces and is configured for processing communication signals from the communication interface and for providing processing results as output signals at the output interface. The processing device is configured such that a safety-related output signal is provided at the output interface if a safety signal, which is contained in a communication signal, is present, and if at least two data records, which are respectively provided in a communication signal, are encoded differently and are directed at the processing device, conform with one another.
    Type: Application
    Filed: November 7, 2017
    Publication date: May 24, 2018
    Inventors: Martin Gehrke, Martin Maier, Roland Kalberer, Andreas Herzog, Ralf Forcht
  • Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
    Patent number: 9970006
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: May 15, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi, Muthiah Manoharan, Tuyen Nguyen
  • Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180100150
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
    Type: Application
    Filed: November 1, 2017
    Publication date: April 12, 2018
    Inventors: Akin Akinc, Gregory Hinkle, Martin Maier, James Butler, Jingxuan Liu
  • TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180087058
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Application
    Filed: September 5, 2017
    Publication date: March 29, 2018
    Inventors: James Butler, Brian Bettencourt, Kallanthottathil G. Rajeev, Martin Maier, Klaus Charisse
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180087054
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: October 12, 2017
    Publication date: March 29, 2018
    Inventors: William Querbes, Kevin Fitzgerald, James Butler, Stephanie Williams, Gregory Hinkle, Martin Maier
  • Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes
    Publication number: 20180066255
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.
    Type: Application
    Filed: July 6, 2017
    Publication date: March 8, 2018
    Inventors: Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
  • LIPID CONTAINING FORMULATIONS
    Publication number: 20180065918
    Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
    Type: Application
    Filed: April 20, 2017
    Publication date: March 8, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc, Jayaprakash K. Nair, Muthusamy Jayaraman, Martin Maier
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    Publication number: 20180065920
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: May 15, 2017
    Publication date: March 8, 2018
    Inventors: Muthiah Manoharan, Martin Maier, Muthusamy Jayaraman, Shigeo Matsuda, Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Akin Akinc, Thomas A. Baillie
  • NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    Publication number: 20180043009
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Application
    Filed: May 23, 2017
    Publication date: February 15, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • Method for manufacturing a solenoid valve
    Patent number: 9885101
    Abstract: A method is described for manufacturing a solenoid valve, in particular a fuel injector, the solenoid valve having a valve needle which is movably guided in the axial direction, a magnet core and an armature which is situated axially diametrically opposed to the magnet core, the armature being situated on the valve needle, the armature having a first base material and a first reinforcing element and the magnet core having a second base material and a second reinforcing element. The method has one method step. The first reinforcing element is applied to the first base material and/or the second reinforcing element is applied to the second base material during the method step with the aid of molten bath spraying or with the aid of cold gas spraying.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: February 6, 2018
    Assignee: ROBERT BOSCH GMBH
    Inventors: Juergen Graner, Martin Maier, Anselm Berg
  • Carbohydrate conjugates as delivery agents for oligonucleotides
    Patent number: 9867882
    Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula(I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: January 16, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash Nair, Martin Maier
  • MODIFIED RNAi AGENTS
    Publication number: 20180008724
    Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 11, 2018
    Inventors: Kallanthottathil G. RAJEEV, Tracy ZIMMERMANN, Muthiah MANOHARAN, Martin MAIER, Satyanarayana KUCHIMANCHI, Klaus CHARISSE
  • REVERSIR TM COMPOUNDS
    Publication number: 20170369872
    Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 28, 2017
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Vasant JADHAV, John MARAGANORE, Martin MAIER, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Akin AKINC, Ivan ZLATEV
  • Complement component C5 iRNA compositions and methods of use thereof
    Patent number: 9850488
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 26, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, James Butler, Brian Bettencourt, Anna Borodovsky, Satyanarayana Kuchimanchi, Klaus Charisse, Muthiah Manoharan, Martin Maier, Kallanthottathil G. Rajeev, Donald Foster
  • TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170362594
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Application
    Filed: May 24, 2017
    Publication date: December 21, 2017
    Inventors: James Butler, Martin Maier, Kevin Fitzgerald, Shannon Fishman, Donald Foster, Vasant Jadhav, Stuart Milstein
  • HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170349900
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.
    Type: Application
    Filed: May 10, 2017
    Publication date: December 7, 2017
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Stuart Milstein, Muthiah Manoharan, Kallanthottathil G. Rajeev
  • HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170349901
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.
    Type: Application
    Filed: May 10, 2017
    Publication date: December 7, 2017
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Muthiah Manoharan, Stuart Milstein, Svetlana Shulga Morskaya, Kallanthottathil G. Rajeev, Huilei Xu
  • Fuel distributor
    Patent number: 9810189
    Abstract: A fuel distributor, which is used, in particular, for fuel injection systems of mixture-compressing, internal combustion engines having externally supplied ignition, includes a distributor pipe, a first holder and at least one second holder. The distributor pipe has a longitudinal axis. In this connection, the first holder and the second holder are situated at the distributor pipe so as to be axially set apart from one another with respect to the longitudinal axis. The distributor pipe is designed to allow axial length compensation. It is also possible for at least one holder to be designed to allow axial length compensation.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: November 7, 2017
    Assignee: ROBERT BOSCH GMBH
    Inventors: Martin Maier, Martin Goehner, Markus Feigl, Helmut Schneider, Nikolaus Hautmann, Dietmar Uhlenbrock, Holger Uhrig